A statement released earlier today by Zacks Investment Research about Edwards Lifesciences Corp (NYSE:EW) bumps the target price to $127.00

Zacks Investment Research upped the target of Edwards Lifesciences Corp (NYSE:EW) to $127.00 reporting a possible upside of 0.12%.

Previously on 5/15/2017, Vetr Inc. released a statement about Edwards Lifesciences Corp (NYSE:EW) increased the target price from $0.00 to $124.67. At the time, this indicated a possible upside of 0.10%.

Just yesterday Edwards Lifesciences Corp (NYSE:EW) traded 0.19% higher at $113.43. The company’s 50-day moving average is $100.68 and its 200-day moving average is $94.26. The last stock close price is up 20.57% from the 200-day moving average, compared to the S&P 500 which has increased 0.02% over the same time. 2,524,786 shares of the stock were exchanged, up from an average trading volume of 1,992,670

See Chart Below

Edwards Lifesciences Corp has a 52 week low of $81.12 and a 52 week high of $121.75 with a P/E ratio of 37.78 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its target price, a total of 22 brokers have issued a report on the stock. The consensus target price is $117.68 with zero equity analysts rating the company a strong buy, zero equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and lastly zero equity analysts rating the company a sell.

Brief Synopsis About Edwards Lifesciences Corp (NYSE:EW)

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care. It also develops hemodynamic monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. It is developing products, such as the Edwards SAPIEN 3 Ultra System and Edwards SAPIEN XT transcatheter heart valve, among others. Its Transcatheter Heart Valve Therapy and Surgical Heart Valve Therapy products are manufactured in the United States, Singapore and Switzerland. Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic.